Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren's disease.
CRAMP may play a protective role in Sjögren's disease, with gut microbiota influencing its expression, but further research is needed to confirm these findings in humans.
Where it sits
this study against the rest of the ll-37 corpusSummary and findings
This study investigated the effects of cathelicidin-related antimicrobial peptide (CRAMP) on Sjögren's disease (SjD) using salivary gland tissues from SjD patients and two mouse models. Exogenous CRAMP administration improved the SjD phenotype, while CRAMP knockdown exacerbated disease severity. The study highlights the role of gut microbiota in regulating CRAMP expression.
Abstract
Sjögren's disease (SjD) is a systemic autoimmune disorder marked by lymphocytic infiltration of exocrine glands. To date, its pathogenesis remains incompletely understood. Cathelicidins are a widespread family of host-defense antimicrobial peptides, primarily recognized for their antimicrobial properties, and are now increasingly appreciated for their immunomodulatory functions. However, the role of cathelicidin in the immunopathogenesis of SjD remains unknown. In this study, we investigated the effects of cathelicidin-related antimicrobial peptide (CRAMP) on SjD and the underlying mechanisms. Salivary gland tissues from SjD patients and controls were collected. Two established mouse models of SjD, i.e., the non-obese diabetic (NOD) mice that spontaneously develop SjD-like disease features, and salivary gland protein-induced experimental SjD mice, were used for the studies. Our data showed that salivary gland acinar cells produce cathelicidin, and that production is impaired in both SjD patients and mice compared to the control group. Moreover, CRAMP plays a protective role in SjD, as exogenous CRAMP administration improved the SjD phenotype, whereas CRAMP knockdown exacerbated disease severity. By combining RNA sequencing with pharmacological inhibitors, we demonstrated that CRAMP acts through formyl peptide receptor 2 (FPR2) to inhibit the PI3K/AKT signaling pathway, thereby reducing the autoimmune response in the salivary glands. Furthermore, we identified gut microbiota and its metabolite, propionic acid, as critical regulators of CRAMP expression in salivary gland acinar cells. Treatment with propionic acid or transfer of gut microbiota from a non-autoimmune control strain to SjD mice increased CRAMP levels and alleviated disease severity, highlighting a pivotal gut-salivary gland axis in SjD pathogenesis. Overall, these findings underscore the pivotal role of CRAMP in protecting against SjD and pave the way for future microbiota-based therapies.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.